Tag: cannabis industry

  • In Recovery, on Suboxone, and in the Weed Business

    In Recovery, on Suboxone, and in the Weed Business

    In print and online, I preached cannabis. In life, I practiced therapy and Suboxone.

    I had a few days left on my Suboxone script when I interviewed Justin “Bong King.” He was a professional bong-racer and self-described champion of the competitive smoking circuit. An affable guy, nonetheless his was an image of American cannabis long past, pushed aside by marketing grads and stay-at-home moms who sold branded CBD and touted the benefits of micro-dosing. 

    But Justin drew a crowd, and an entourage to boot. And his natural talent for hitting the fastest gram of weed would corner me into compromising my recovery.

    Throughout my career as a cannabis journalist, I’ve kept silent about my sobriety. Finding freelance gigs is hard enough without the added burden of having to be that guy. Besides, if I learned anything from active addiction, it was how to lie at my job.

    Covering Cannabis Events and Lying About My Sobriety

    But as time passed, I felt withdrawn and disconnected. My recovery had no place in the cannabis industry. Moreover, medication-assisted treatment (MAT) seemed anathema to its goals, according to experts and the news. Rep. Matt Gaetz openly questioned whether buprenorphine and methadone are “a more effective offramp [to opioid use disorder] than medical cannabis.” CNN announced that CBD cures heroin addiction. And the editors of Leafly figured out how to combat the opioid crisis with medical cannabis two years prior.

    After 20 years, recovery had finally become routine. As a cannabis journalist; as an editor in chief — so had my lies.

    Some lies were easy. Weekly therapy appointments usually coincided with editorial meetings or deadlines. I worked from home, my boss was lax, and anyway, I kept hours around the clock. Monthly visits to my psych and 30-day Suboxone refills upped the number of undisclosed appointments I logged, but still, no one seemed to care.

    On assignment was a different story. I covered cannabis expos or dispensary openings — events where the drug laws were lax and the supply was liberal. At a hotel in Hell’s Kitchen, I spent three nights alone avoiding networking galas and after-parties hosted by music moguls turned industry entrepreneurs. In the world’s largest dispensary off the Las Vegas strip, I dodged more questions than I asked when leaving empty-handed. With hand waves and head shakes and less-than-assertive no’s, I passed over pot by lying about my sobriety.

    But face to face with Justin “Bong King,” there was nowhere to hide — no hotel room to run to, no door from which to make a quick exit. There was a crowd around us, boxing us in as he finished his gram smoking demonstration. I shook his hand and stumbled over my words as I signed off the segment on camera.

    It was either a contact high or placebo effect, or maybe just panic anticipating the piss test I would take in the next few days.

    Intensive Outpatient: 12 Steps and Scoring Drugs

    When I had about two months left in my treatment program, I walked out of group for good. It was an intensive outpatient program; a six-month IOP run by Philly’s NHS that championed the Big Book and 90 days. For a minute it worked, but it’s drug rehab mired in a puritan past. The 12 steps are great, but they shouldn’t be a front-line defense.

    Besides, all I did there was make friends and score drugs. Thirty addicts in a room is an excellent opportunity to network and learn.

    By Easter Sunday that year, I felt broken. I was in a dirty motel on Route 1, hopped up on Benzedrex cottons and a $60 baggie of hex-en I purchased online from China. After 20 years of addiction, I had no drug of choice, save for anything that made me high.

    My wife and kids back home slept together in one bed, a little less worried than the last time I disappeared. I was out of work and estranged from everyone. My best friend joined AA and realized I was one of his people, places, and things.

    All I had was my family, and I was losing them too.

    One lie allowed my addictions to grow without the worry of what would happen tomorrow. It’s the lie I told myself when I stole my ex-wife’s Dilaudid two days after her shoulder surgery. It’s the lie that made me laugh when I snorted enough Adderall to make my nose blue. And it’s the same lie that made me indignant when my ex-girlfriend’s brother became angry that I was a sloppy drunk in front of his small children.

    On the Monday after Easter, I drove home before sunrise. It was dark and muggy and difficult to see through my tears and dilated pupils. When I got home, I faced my wife and children and ended the lie that had followed me through two decades of addiction.

    “I can’t stop,” I whispered. That week, I discussed MAT options with my doctor. I’ve been in recovery since that day.

    Cannabis as the Magic Bullet for the Opioid Crisis?

    Tyler Sash won the Super Bowl in his rookie year with the New York Giants. At the time, he didn’t know he only had a few years left to live. A sixth-round draft pick out of Iowa, he overdosed on a combination of methadone and hydrocodone at the age of 27.

    “[He] asked if he could smoke marijuana for his pain like the other players,” recalled his one-time girlfriend, former Miss Iowa and reality-show contestant Jessica VerSteeg. I interviewed VerSteeg when she was promoting a new blockchain-bitcoin something-or-other product in the cannabis space. She recounted Sash’s tragic tale during our interview, explaining how it became the backbone of her business.

    “I wanted to change the way that other people saw cannabis,” she said.

    VerSteeg’s article drew in readers, as did most CEO and celebrity interviews. Her story reminded me of how lonely my secrecy about my recovery had become. I often wished I could reach out and say that I understood. There are millions of people with substance use disorders, and we’re all so alone.

    But like most of the executive class in the cannabis industry, her hot take on opioids ended up being bullshit. Conventional wisdom in the cannabis industry had run somewhat amok on this topic, and it forced me, I felt, into compromising everything.

    There was the DEA agent who was so disgusted with opioids that he became a cannabis executive. Without irony, he told me that more research would prove the plant’s medicinal value. The head of an “innovation accelerator” in my city held a conference on the role of medical cannabis in the opioid crisis. He quoted research showing that states with medical cannabis laws have lower rates of opioid overdose deaths. Cannabis, they were convinced, would solve the opioid epidemic.

    But Where’s the Evidence?

    “Morphine, when it was introduced, was promised to cure what they called alcoholism at the time,” Dr. Keith Humphreys told me. A professor of psychiatry and behavioral sciences at Stanford University, he’s also worked at the White House Office of National Drug Control Policy under Presidents Bush and Obama. “Then, people got addicted to morphine, and cocaine was introduced.”

    He continued: “In general, there’s been this enthusiasm of if we just add a different class of addictive drug on top then that will drive the other addictions out. Generally, what happens is we get more addiction to that drug, and we still have the original problem.”

    I spoke with Dr. Humphreys after reading his research on cannabis laws and opioid overdose mortality rates. Contrary to conventional wisdom, he found the correlation to be spurious at best. It’s alarming — though not unsurprising — to see the industry ignore his findings. Several states, including Pennsylvania, where I live, approved opioid use disorder as a qualifying condition for medical cannabis.

    “I couldn’t recommend something medically without clinical trials, well-controlled by credible groups [and] checked for safety,” Dr. Humphreys said. He explained that in the case of cannabis, there was little more than these state-level correlational studies. “None of that has been done.”

    “I’m amazed and disappointed that we don’t care more about people who are addicted to heroin [and other] opioids, that we would wave through something like [medical cannabis] without making sure that it will help people, not hurt them,” he continued, noting that cannabis has shown no efficacy as either a replacement for or an adjunct to any MAT therapy.

    Listening to Dr. Humphreys made me realize how little I stand up for what I believe. Sometimes, when you’re an addict and you lie so much, you lose any sense of truth.

    Tyler Sash’s family asked Jessica VerSteeg to stop using his name to promote her business. According to a report in the Des Moines Register, they didn’t want his name associated with drugs anymore, neither opioids nor marijuana. VerSteeg refused, repeating the story she told me to several news outlets.

    For two years, I wrote about and reported on the emerging cannabis industry while hiding my ongoing recovery. In print and online, I preached cannabis while practicing therapy and Suboxone.

    Even in recovery, you can still have regrets.

    View the original article at thefix.com

  • Cannabis Industry Searches for Consistent High

    Cannabis Industry Searches for Consistent High

    “No one ever knows what they’re getting, and it’s a huge problem. It’s making it so the [cannabis] industry doesn’t work very well,” said one scientific expert about the lack of consistency.

    The cannabis industry is expanding rapidly, but scientists and investors are still chasing an elusive goal: a cannabis plant that can provide a predictable high when it is smoked. 

    Although tinctures, edibles and other products made with cannabis extracts can offer more exact amounts of cannabinoids that make the effects more consistent, industry leaders say that consumers want a bud that can offer the same type of reliable experience. Right now, that doesn’t exist. 

    “No one ever knows what they’re getting, and it’s a huge problem,” Mowgli Holmes, chief scientific officer of Phylos Bioscience in Portland, Oregon, told NBC News. “It’s making it so the industry doesn’t work very well. Often it’s way too strong. It’s Russian roulette. New customers get burned and don’t come back.”

    Jon Vaught, CEO of agricultural technology firm Front Range Biosciences, said that people who want to know what effects they’ll experience when using cannabis often opt for manufactured products because they better understand what they’re getting. Still, there is a demand for a marijuana flower that offers the same consistency. 

    “Folks are using it in new forms, low-dose, edibles, tinctures, capsules, and what they care about is the effect,” he said. “But there are consumers who want to consume cannabis the way they have for years. They like the things they know.”

    Growers have been chasing the goal for years but now there are more financial incentives than ever to get a product to market, with marijuana flower sales expected to reach $8.5 billion annually by 2022. 

    “That’s been the goal forever,” said Greg Zuckert, vice president of cultivation for cannabis producer Harvest Health & Recreation. 

    Some growers and researchers are analyzing the DNA of marijuana plants to better understand the effects they’ll have when smoked. 

    “I’m working on genetic markers and looking at taking DNA from different species, trying to create genetics to fit neurochemical profiles to treat different ailments,” Zukert said. “These are exciting things.”

    Growers who use specific genetic traits may be able to patent their plants, leading to an industry full of brand-name marijuana varieties that are much more tightly controlled than the strains pot aficionados are familiar with today. 

    “In the future, those strains will all be irrelevant,” said Marcus Walker, founder of Cult Classics Seeds in Colorado. 

    Attorney Gary Hiller of California’s Napro Research, a California seed-to-sale producer, said that various cannabis plants will likely become proprietary.

    “It doesn’t matter what it’s called once it’s correctly characterized and a good breeder can replicate it,” he said. 

    View the original article at thefix.com

  • Senatorial Candidate Gary Johnson Reveals Cannabis Industry Connections

    Senatorial Candidate Gary Johnson Reveals Cannabis Industry Connections

    The former New Mexico governor disclosed his ties to the cannabis industry amid his run for U.S. Senate.

    Two-time Libertarian presidential candidate Gary Johnson has revealed his personal financial ties to the marijuana industry, which have some observers concerned about a possible conflict of interest in regard to his bid for New Mexico’s Senate seat.

    Disclosing one’s financial investments is part of the campaign process, and in recent Senate filings, Johnson stated that he owns more than $250,000 in stock from the Las Vegas, Nevada-based cannabis company Kush, as well as profit shares from a cannabis industry funding group, and capital gains from stock from another cannabis company, for which he served as CEO.

    Johnson, who previously served two terms as governor of New Mexico, has dismissed concerns about the potential conflict, stating that his political interests outweigh his connections to the industry.

    Between bids for the White House on the Libertarian ticket in 2012 and 2016, Johnson earned at least $100,000 in capital gains from stock earned during his tenure as CEO of Cannabis Sativa, and participates in a profit-sharing arrangement with the investment fund CB1 Capital, which provides funding exclusively for cannabis industry entities. Johnson serves as one of the fund’s key advisers. 

    As the Albuquerque Journal noted, issues of conflict over Johnson’s connections to the cannabis industry arose in regard to his candidacy for the U.S. Senate, which he announced in August 2018. Johnson is running on the Libertarian ticket against Democratic incumbent Martin Heinrich.

    Both Johnson and Heinrich are in favor of legalizing marijuana at the federal level, while Republican candidate Mick Rich is opposed to such efforts.

    But Johnson has waved off such worries by noting that he has been in support of legalized marijuana since the 1990s, which he described as a “career-ending move” two decades ago. “The last thing that I ever dreamed of happening is that somehow I would make money off this,” he said.

    Currently, medical marijuana is legal in the state of New Mexico, but marijuana for recreational use is not. New Mexico residents consume a considerable amount of marijuana from both the legal and black markets; approximately 27,000 individuals are registered medical marijuana patients, while more than 135,000 claimed that they consume recreational marijuana on a regular basis.

    As High Times noted, if the state made marijuana legal, industry investors could stand to make a sizable profit from sales. Researchers have estimated that more than 57 metric tons would be used in the state annually, which could yield a profit of approximately $412 million, with the possibility of growing to as much as $677 million.

    View the original article at thefix.com

  • The Cannabis Industry Wants You To Ditch The Word "Stoner"

    The Cannabis Industry Wants You To Ditch The Word "Stoner"

    A new ad campaign is pushing to end marijuana-related stigma.

    The word “stoner” immediately brings to mind a specific stereotype: a low achiever clouded in smoke and looking for a snack. Now, a retail pot company in California has launched a $2 million advertising campaign trying to convince the public to let the world stoner go up in smoke.

    “That word can be used to negatively stereotype people,” Daniel Yi, senior vice president of communications at MedMen, which operates 14 retail pot stores, told The LA Times. “We want to take that stigma away. We want to make marijuana mainstream.”

    The ads feature actors dressed as police officers, nurses, teachers and other professionals. Next to the individual is the word “stoner” with a slash through it. Yi said the ads are meant to address the stigma that still exists around smoking pot, even in states like California where recreational use is legal. 

    Yi said that the recent controversy over Elon Musk smoking marijuana on a YouTube show shows that there is still a long way to go before cannabis is accepted as mainstream. 

    “The Stephen Colbert show (on CBS) does this thing where Colbert takes shots of tequila with some of his guests,” Yi said. “That doesn’t show up on the front page of the LA Times. But Musk smokes one blunt on “The Joe Rogan Experience” and it gets lots of press coverage. Alcohol is acceptable, marijuana isn’t.”

    MedMen’s ads are just one way that the marijuana industry is trying to rebrand smoking cannabis. Other retailers won’t use the term “pot.”

    “It’s legal now,” said Brooke Brun, cofounder of Kb Pure Essentials, a company that makes CBD products marketed for health and wellness. “People don’t feel so bad about asking for it, or being seen at a CBD booth.” 

    However, industry insiders said that stigma will be reduced the most as marijuana use becomes legalized with no social consequences. 

    “The negative prophecies didn’t come true,” said Dallin Young, executive director of the Assn. of Cannabis Professionals in San Diego. “California hasn’t turned into some Mad Max world.” 

    While some people took issue with the ads, other residents of San Diego — where some of the billboard are located — said the campaign is really nothing new. 

    “The alcohol industry has for eons shown advertisements of imbibers in all professions appearing to lead normal, healthy lives,” Don Paret of San Diego said. “Why (shouldn’t) the pot industry do the same? MedMen’s attempt to create a more legitimate image of pot users is no different than the alcohol industry portraying a similar image.” 

    Others weren’t sure that people would be able to stop using the word ‘stoner.’ 

    “While ‘stoner’ may conjure images of a permanently buzzed Jeff Spicoli-type [from Fast Times at Ridgemont High], I think trying to stop people from using it is a pointless and losing battle,” said California resident Gary Deacon. “Either embrace and reclaim the epithet by showing that ‘stoners’ can be productive contributors to society, or promote an alternate term for people to use.”

    View the original article at thefix.com

  • "Social Equity" Program To Help Those Impacted By Drug War In Massachusetts

    "Social Equity" Program To Help Those Impacted By Drug War In Massachusetts

    The programs aims to help people who have been disproportionately affected by the drug war enter the cannabis industry with ease.

    The state of Massachusetts is rolling out a new “social equity” program to help certain individuals navigate the legal cannabis industry.

    Cannabis for adult (or “recreational”) use is a booming industry. It is legal in nine states and the District of Columbia, while more, including New Jersey and New York, may follow.

    Equity programs already exist in California, but the one in Massachusetts would be the first in the nation to be applied statewide.

    The idea is to provide assistance to people who have been disproportionately affected by the government’s long-waged “war on drugs.”

    To be eligible for the Massachusetts program, a person must either have a past drug conviction or be the spouse or child of a person with a drug conviction, who has lived in the state for the last year; or they must have lived in a community deemed an “area of disproportionate impact” for at least five years and earn below 400% of the federal poverty level.

    Eligible applicants will receive mentoring, technical assistance, and skills training to help them enter the cannabis industry with ease.

    “The social equity program is designed to create sustainable pathways into the adult use cannabis industry for both individuals and businesses,” said Shekia Scott, the director of community outreach for the Cannabis Control Commission (CCC), which was tasked with helping those disproportionately affected by the criminalization of marijuana get in on the growing industry.

    The program’s goal is to create a comprehensive program tailored to each applicant at any skill level—whether they want to start a business or find an entry level job.

    “We want applicants to specify their needs so we can meet them where they are,” said Scott, who introduced the social equity program at a Tuesday (June 26) meeting of the CCC. “We’re not making a one-size-fits-all program, that we know usually doesn’t fit all.”

    While the Massachusetts program does not specifically target certain people of color, inevitably many black and Latino residents will be eligible to participate.

    According to the American Civil Liberties Union, black Americans are arrested for cannabis possession at more than 3.7 times the rate of whites, despite the fact that marijuana is used at comparable rates by both groups.

    According to Marijuana Business Daily, owners and founders within the cannabis industry are 81% white, while just 4.3% are black and 5.7% are Latino.

    View the original article at thefix.com